Vancomycin-intermediate resistance in Staphylococcus aureus

Area of Science:

• Microbiology
• Genetics
• Infectious Diseases

Background:

• Vancomycin-intermediate Staphylococcus aureus (VISA) and hetero-VISA (hVISA) are significant challenges in treating methicillin-resistant S. aureus (MRSA) infections.
• Unlike vancomycin resistance in other bacteria, VISA emerges through the accumulation of genetic mutations.
• Understanding these resistance mechanisms is crucial for developing effective treatment strategies.

Approach:

• This work provides a concise overview of recent advancements in understanding the genetic underpinnings of hVISA, VISA, and the newly identified slow VISA (sVISA) phenotype.
• The review synthesizes current knowledge on the genetic basis of vancomycin resistance in Staphylococcus aureus.
• Focuses on the genetic mechanisms driving VISA and related phenotypes.

Key Points:

• VISA and hVISA have been recognized for nearly two decades as major obstacles in MRSA chemotherapy.
• VISA resistance is characterized by a complex genetic basis involving accumulated mutations.
• Recent research has identified a new phenotype, slow VISA (sVISA), adding to the complexity of vancomycin resistance.

Conclusions:

• The genetic mechanisms driving VISA, hVISA, and sVISA are diverse and complex.
• Continued research into the genetics of these resistant strains is essential for overcoming treatment limitations.
• Understanding the genetic evolution of vancomycin resistance in S. aureus is critical for public health.